Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced it has received an award of up to $856,250 from Breakthrough T1D, the leading global type 1 ...
AZoLifeSciences on MSN
Syntax Bio develops CRISPR technology to program stem cell gene activity
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback